Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms.

Company profile
Ticker
CSBR
Exchange
Website
CEO
Ronnie Morris
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
CHAMPIONS BIOTECHNOLOGY, INC., CHAMPIONS SPORTS INC
SEC CIK
Corporate docs
IRS number
521401755
CSBR stock data
News
Champions Oncology Q4 EPS $(0.02) Misses $0.02 Estimate, Sales $12.90M Beat $12.72M Estimate
21 Jul 22
Earnings Scheduled For July 21, 2022
21 Jul 22
A Preview Of Champions Oncology's Earnings
20 Jul 22
Champions Oncology Announces A Partnership With Cyclica To Develop Small Molecule Therapeutics; Terms Not Disclosed
31 May 22
Investment data
Securities sold
Number of investors
Calendar
22 Jul 22
12 Aug 22
30 Apr 23
Financial summary
Quarter (USD) | Apr 22 | Jan 22 | Oct 21 | Jul 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 22 | Apr 21 | Apr 20 | Apr 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.01M | 9.01M | 9.01M | 9.01M | 9.01M | 9.01M |
Cash burn (monthly) | (no burn) | (no burn) | 115.33K | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 395.8K | n/a | n/a | n/a |
Cash remaining | n/a | n/a | 8.61M | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | 74.7 | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Nov 21 | Tobin Scott R | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 10.1 | 14,851 | 150K | 14,851 |
5 Nov 21 | Philip P. Breitfeld | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 10.1 | 8,045 | 81.25K | 8,045 |
5 Nov 21 | Ackerman Joel | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 10.1 | 18,564 | 187.5K | 18,564 |
5 Nov 21 | Sidransky David | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 10.1 | 8,045 | 81.25K | 8,045 |
5 Nov 21 | Mendelson Daniel Newman | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 10.1 | 13,614 | 137.5K | 13,614 |
Institutional ownership, Q1 2022
50.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 16 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 56.33M |
Total shares | 6.82M |
Total puts | 0 |
Total calls | 224.7K |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Battery Management | 2.42M | $19.69M |
NEA Management | 1.71M | $13.93M |
West Elk Partners | 676.94K | $6.4M |
Vanguard | 345.84K | $2.81M |
Millrace Asset | 328.98K | $2.68M |
Tocqueville Asset Management | 252.46K | $2.05M |
Renaissance Technologies | 169.94K | $1.38M |
BLK Blackrock | 122.8K | $999K |
Essex Investment Management | 115.08K | $936K |
Dimensional Fund Advisors | 111.92K | $910K |
Financial report summary
?Competition
Vyant BioRisks
- We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability.
- We may incur greater costs than anticipated, which could result in sustained losses.
- We may not be able to implement our business strategies which could impair our ability to continue operations.
- Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.
- If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected.
- Any health crisis impacting our colony of laboratory mice could have a negative impact on our business.
- We have limited experience marketing and selling our products and may need to rely on third parties to successfully market and sell our products and generate revenues.
- We will continue to be dependent upon key employees.
- Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies.
- If we are unable to protect our intellectual property, we may not be able to compete as effectively.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition.
- Research service studies are subject to cancellation based on changes in customer’s development plans.
- We face competition in the life science market for computational software and for bioinformatics products.
- Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.
- We have a limited market for our common stock, which makes our securities very speculative.
- Investment in our common stock may be diluted if we issue additional shares in the future.
- Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it.
- Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by stockholders.
- Our management and four significant stockholders collectively own a substantial majority of our common stock.
- We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.
- If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline.
- A pandemic, epidemic, or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business and we are unable to predict the potential impact.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
assest, attempt, automated, bringing, catastrophic, conflict, cyber, cybersecurity, denial, efficiency, energy, expose, feasibility, formalized, fuel, geopolitical, hacking, heightened, ID, interruption, Italy, leakage, left, LEONE, malfeasance, manual, Milan, military, mitigate, monitor, monitored, occupancy, passed, phishing, pose, principal, prolonged, proper, ransomware, Russia, shutdown, storage, store, stored, strength, transmit, turmoil, Ukraine, variety, viability, violation, vulnerable, XIII
Removed:
achieved, adjustment, ahead, assume, attribution, book, burden, capitalizing, captured, CCA, classify, clearance, companion, Conclusion, conjunction, conventional, decided, decision, device, directed, disposal, disposed, draft, enforcement, exclude, exempt, exercisable, grantor, improved, inclusive, influence, inherent, intent, legislative, limiting, lowering, managed, manufacturer, mature, meaningful, measurement, measuring, Medicaid, Medicare, modified, nonemployee, notified, phased, prescription, proposed, rare, recent, reform, reimbursement, rejection, requirement, retrospective, scope, shift, taxing, trend
Financial reports
Current reports
8-K
Champions Oncology Reports Quarterly Revenue of $12.9 Million
21 Jul 22
8-K
Champions Oncology Reports Record Quarterly Revenue of $13.2 Million
15 Mar 22
8-K
Champions Oncology Reports Record Quarterly Revenue of $11.8 Million
13 Dec 21
8-K
Submission of Matters to a Vote of Security Holders
21 Oct 21
8-K
Champions Oncology Reports Record Quarterly Revenue of $11.3 Million
13 Sep 21
8-K
Champions Oncology Reports Quarterly Revenue of $10.6 Million
22 Jul 21
8-K
Champions Oncology Reports Record Quarterly Revenue of $10.8 Million
11 Mar 21
8-K
Departure of Directors or Certain Officers
12 Feb 21
8-K
Champions Oncology Reports Record Quarterly Revenue of $10.1 Million
14 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
21 Oct 20
Registration and prospectus
424B4
Prospectus supplement with pricing info
9 Jun 16
S-1/A
IPO registration (amended)
23 May 16
424B3
Prospectus supplement
14 Oct 15
POS AM
Prospectus update (post-effective amendment)
24 Sep 15
8-A12B
Registration of securities on exchange
19 Aug 15
424B3
Prospectus supplement
18 May 15
S-1
IPO registration
10 May 15
D
$14M in equity / options, sold $14M, 11 investors
24 Mar 15
D
$2M in debt / options / securities to be acquired, sold $2M, 2 investors
11 Dec 14
Other
EFFECT
Notice of effectiveness
8 Jun 16
CORRESP
Correspondence with SEC
7 Jun 16
CORRESP
Correspondence with SEC
7 Jun 16
CORRESP
Correspondence with SEC
22 May 16
UPLOAD
Letter from SEC
4 May 16
EFFECT
Notice of effectiveness
12 Oct 15
EFFECT
Notice of effectiveness
18 May 15
CORRESP
Correspondence with SEC
24 Mar 15
UPLOAD
Letter from SEC
24 Mar 15
UPLOAD
Letter from SEC
23 Mar 15
Ownership
SC 13G/A
CHAMPIONS ONCOLOGY / West Elk Partners ownership change
14 Feb 22
4
CHAMPIONS ONCOLOGY / DAVID SIDRANSKY ownership change
9 Nov 21
4
CHAMPIONS ONCOLOGY / Daniel Newman Mendelson ownership change
9 Nov 21
4
CHAMPIONS ONCOLOGY / Philip P. Breitfeld ownership change
9 Nov 21
4
CHAMPIONS ONCOLOGY / JOEL ACKERMAN ownership change
9 Nov 21
4
CHAMPIONS ONCOLOGY / SCOTT R TOBIN ownership change
9 Nov 21
4
CHAMPIONS ONCOLOGY / DAVID SIDRANSKY ownership change
19 Oct 21
4
CHAMPIONS ONCOLOGY / SCOTT R TOBIN ownership change
13 Oct 21
SC 13G
CHAMPIONS ONCOLOGY / West Elk Partners ownership change
23 Jul 21
4
CHAMPIONS ONCOLOGY / Philip P. Breitfeld ownership change
25 Mar 21
Transcripts
2022 Q3
Earnings call transcript
16 Mar 22
2022 Q2
Earnings call transcript
14 Dec 21
2022 Q1
Earnings call transcript
14 Sep 21
2021 Q1
Earnings call transcript
14 Sep 20
2020 Q4
Earnings call transcript
27 Jul 20
2020 Q2
Earnings call transcript
16 Dec 19
2020 Q1
Earnings call transcript
16 Sep 19
2019 Q4
Earnings call transcript
15 Jul 19
2019 Q3
Earnings call transcript
18 Mar 19
2019 Q2
Earnings call transcript
17 Dec 18
Reddit threads
Daily Discussion Thread - July 21st, 2022
21 Jul 22
Daily Discussion Thread - March 15th, 2022
15 Mar 22
Daily Discussion Thread - March 10th, 2022
10 Mar 22
Daily Discussion Thread - March 9th, 2022
9 Mar 22
Daily Discussion Thread - March 8th, 2022
8 Mar 22
Daily Discussion Thread - March 7th, 2022
7 Mar 22
(12/16) Thursday's Pre-Market Stock Movers & News
16 Dec 21
(12/16) Thursday's Pre-Market Stock Movers & News
16 Dec 21
(12/15) Wednesday's Pre-Market Stock Movers & News
15 Dec 21
(12/15) Wednesday's Pre-Market Stock Movers & News
15 Dec 21